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 Results: We enrolled 177 COPD patients (112 men) with a 
mean age of 64 years (range 42–90), of whom 35 (20%) had 
an ESS score above 10. During nocturnal polygraphy, 33 pa-
tients (19%) had evidence of OSA. In multivariate analysis, 
BMI and pack years were positively associated with AHI, in-
dependent of other significant AHI determinants from uni-
variate analysis. Arterial hypertension and diabetes were 
more common in patients with the overlap syndrome.  Con-
clusions: Almost 20% of COPD patients also have OSA. BMI 
and smoking history seem to be predictors of the overlap 
syndrome, and these patients may be more often affected 
by hypertension and diabetes.  © 2014 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) is a 
chronic inflammatory response of the airways and lungs 
to noxious particles and gases and is usually progressive 
 [1] . Comorbidities, such as cardiovascular disease, play 
an important role regarding the morbidity and mortality 
in COPD  [2] . The combination of both COPD and ob-
structive sleep apnea (OSA) has been described as the 
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 Abstract 
 Background: The occurrence of both chronic obstructive 
pulmonary disease (COPD) and obstructive sleep apnea 
(OSA) in an individual patient has been described as ‘overlap 
syndrome’, which has been associated with poor prognosis. 
Little is known about the possible predictors of the overlap 
syndrome and its association with comorbidities contribut-
ing to impaired outcome.  Objectives: This study aimed to 
evaluate the prevalence and possible predictors of the over-
lap syndrome and its association with comorbidities in a co-
hort of COPD patients.  Methods: Individuals with COPD 
(GOLD stages I–IV, risk groups A–D) were recruited from out-
patient clinics. Information on age, gender, body mass index 
(BMI), smoking status, Epworth sleepiness scale (ESS), COPD 
assessment test, comorbidities, medications and exacerba-
tions in the past year was collected and a spirometry was 
performed. Participants underwent a nocturnal polygraphy 
using the ApneaLink TM device at home. An apnea-hypopnea 
index (AHI) >10 per hour was considered to indicate OSA. 
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‘overlap syndrome’  [3, 4] . OSA is characterized by repet-
itive episodes of upper airway collapse leading to apnea 
and hypopnea associated with intrathoracic pressure 
swings, intermittent hypoxia and arousals from sleep 
with consecutive activation of the sympathetic nervous 
system  [5] . There is conflicting data about the prevalence 
and the predictors of the overlap syndrome. The preva-
lence of COPD and OSA in the middle-aged Western 
population has been estimated to be as high as 19  [6, 7] 
and 30%  [8, 9] , respectively. The prevalence of the overlap 
syndrome seems to vary between 11 and 41%, dependent 
on the population studied  [10–13] .
 The coexistence of both diseases in an individual pa-
tient may be associated with poor outcome as patients 
with the overlap syndrome seem to have a higher mortal-
ity than patients with either COPD or OSA alone  [14] . An 
adequate treatment may reduce the rate of hospitalisa-
tions and deaths  [14] . However, despite the poor outcome 
there is still little data on the clinical presentation of pa-
tients with the overlap syndrome and associated comor-
bidities, thus more information is needed in order to 
identify and treat such patients at an early stage. The aim 
of this study was the evaluation of the prevalence and pos-
sible predictors of OSA in a typical cohort of COPD pa-
tients, and to further identify associated comorbidities 
which may contribute to the high risk of mortality in pa-
tients with the overlap syndrome.
 Material and Methods 
 Subjects 
 This study was conducted at the University Hospitals in Ba-
sel and Zurich, Switzerland. Patients between 42 and 90 years 
of age with objectively confirmed COPD according to the Glob-
al Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines were consecutively included in this study  [1] . We ex-
cluded subjects with upper or lower respiratory tract infections 
and an exacerbation of COPD within the most recent 6 weeks. 
All patients signed informed consent and the study was ap-
proved by the ethical committee ‘Beider Basel’ (EK-163/11) and 
the ethical committee of the University Hospital of Zurich (EK-
1734).
 Study Design 
 In this cross-sectional, two-center study, subjects performed a 
spirometry and were accordingly categorized in COPD GOLD 
stages I–IV. In a clinical examination, height, weight, body mass 
index (BMI) and blood pressure were measured. Smoking history 
and exacerbation rate in the most recent 12 months, comorbidities 
and medications were recorded during a structured physician-led 
interview. Participants completed the Epworth sleepiness scale 
(ESS) and the COPD assessment test (CAT). Patients were asked 
to perform an unattended sleep study at home with the Apnea-
Link TM (ResMed, MAP Medicine Technology, Martinsried, 
 Germany) device during one night. Examinations took place be-
tween July 2011 and January 2012.
 Methods 
 Spirometry 
 The degree of airflow limitation was assessed by performing 
both spirometry and COPD staging according to published guide-
lines  [15] .
 Exacerbation Frequency 
 An exacerbation was defined as a sustained worsening of the 
patient’s condition from the stable state and beyond normal day-
to-day variations that was acute at onset and might have warrant-
ed additional treatment, such as antibiotics and/or steroids. Sub-
jects were asked about the number of exacerbations in the most 
recent 12 months  [16] .
 Epworth Sleepiness Scale 
 The ESS is a self-administered item to assess sleep propensity 
during normal daily activities. The German version of the ques-
tionnaire was used in this study  [17] . Clinically relevant daytime 
sleepiness was assumed if individuals had a score of greater than 
10.
 COPD Assessment Test 
 The CAT is a self-assessed questionnaire in which patients have 
to rate eight COPD-related symptoms, on a scale from 0 (impact 
low) to 5 (impact very high). It is used to assess the impact of COPD 
on an individual’s quality of life and has been proven to be reliable, 
repeatable and sensitive for variations in disease severity  [18] .
 Sleep Studies 
 Home sleep studies were performed using the ApneaLink de-
vice. The device records the patient’s nasal respiratory pressure 
signal and finger oximetry during sleep, and has been validated as 
an accurate instrument with which to detect snoring, apnea-hy-
popnea and oxygen desaturations  [19] . The results of the sleep 
study were scored automatically with dedicated software and man-
ual review to ensure the accuracy of the data. Apneas were defined 
as a cessation of airflow lasting more than 10 s and hypopneas as a 
reduction in airflow of at least 30% lasting more than 10 s, associ-
ated with a drop in oxygen saturation of >4%  [19] . An apnea-hy-
popnea index (AHI) of >10 events per hour was considered to in-
dicate the presence of OSA.
 Analysis 
 Data were analyzed using SPSS version 19 and STATA 12 
(StataCorp, College Station, Tex., USA). Data are presented as me-
dian (quartiles) and mean (standard deviation, SD), unless other-
wise stated. Descriptive data analysis was performed and value dis-
tribution was analyzed with the Shapiro-Wilk normality test. Nor-
mally distributed data were analyzed with the t test. If data were 
not distributed normally, the Wilcoxon rank-sum test was used, 
and for categorical variables the χ 2 test was applied. Univariate re-
gression was used to investigate relationships between AHI (de-
pendent variable) and possible determinants. Further multivariate 
analysis involved regression of variables that showed a univariate 
p value <0.1. A p value <0.05 was considered to indicate statistical 
significance.
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 Results 
 Characteristics of the Study Population 
 We recruited 185 patients with diagnosed COPD. 
From these, 6 were excluded on the basis of nocturnal 
treatment with continuous positive airway pressure or 
oxygen therapy, and thus no possibility to perform the 
requested nocturnal sleep studies. A further 2 partici-
pants had to be excluded on the basis of inability to per-
form a valid ApneaLink measurement ( fig. 1 ). A total of 
177 individuals were included in the final analyses. The 
patient characteristics are presented in detail in  table 1 .
 Thirty-five participants (19.8%) had an ESS >10 and 
were considered sleepy. Sixty-one subjects (35%) had an 
AHI of >5 events per hour and 33 patients (19%) had an 
AHI of >10, and thus were considered to have OSA 
( fig.  2 ). Comparing characteristics between the group 
with an AHI  ≤ 10 events per hour and the group with an 
AHI >10 events per hour, individuals with evidence for 
the overlap syndrome presented with higher BMI, higher 
FEV 1 and less frequent exacerbations ( table 2 ; online sup-
pl. table, for all online suppl. material, see www.karger.
com/doi/10.1159/000368615).
 Significantly higher rates of arterial hypertension and 
diabetes mellitus were found in the group of COPD pa-
tients with evidence for OSA. Cardiovascular disease was 
not found to be more frequent in the patients with the 
overlap syndrome compared to patients with COPD 
 Table 1.  Characteristics of the study population
Characteristics Patients (n = 177)
Age, years 63.8 (8.8)
Male/female, n 112/65
BMI, kg/m2 25.4 (21.8/29.5)
Systolic blood pressure, mm Hg 126.5 (116/141)
Current smoker, n 61 (35)
Pack years 40 (24.2/60)
CAT score 15.5 (10/21)
Exacerbations per year, n 0 (0/1)
SpO2 daytime, % 95 (93/96)
FEV1 %pred 57 (32/75.7)
GOLD stage 1, n 25 (14)
GOLD stage 2, n 72 (41)
GOLD stage 3, n 38 (22)
GOLD stage 4, n 42 (24)
AHI, events/h 4 (1/8)
ODI, events/h 4 (2/8)
Mean nocturnal SpO2, % 92 (90/94)
ESS score 6 (4/10)
Arterial hypertension, n 74 (42)
Cardiovascular disease, n 24 (14)
Diabetes mellitus, n 25 (17)
LAMA, n 11 (6)
LABA + GC, n 23 (13)
LAMA + LABA + GC, n 77 (44)
 Age is presented as the mean with SD in parentheses; other values are 
n with percentage in parentheses, or median with percentiles in parenthe-
ses. ODI = Oxygen desaturation index; LAMA = long-acting muscarinic-
antagonist; LABA = long-acting β-agonist; GC = glucocorticosteroid.
Exclusion on the basis of 
inability to perform ApneaLink
(n = 2)
Exclusion on the basis of nocturnal
oxygen or CPAP therapy
(n = 6)
Individuals in final analysis
(n = 177)
Individuals with a diagnosis of COPD
(n = 185)
 Fig. 1. Study flow diagram. CPAP = Continuous positive airway 
pressure. 
0
5
10
15
20
25
30
35
40
AHI >5 AHI >10 AHI >15
P
re
va
le
n
ce
 o
f 
O
SA
 (
%
)
 Fig. 2. Prevalence of OSA in the COPD cohort using different AHI 
events per hour thresholds. 
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alone ( fig. 3 ). In a univariate analysis, male sex, BMI, pack 
years, daytime peripheral oxygen saturation (Sp O 2 ), exac-
erbation rate, mean nocturnal Sp O 2 and diabetes mellitus 
were significantly associated with AHI ( table 3 ).
 In multiple regression analysis, including age, gender, 
BMI, pack years, ESS, daytime Sp O 2 exacerbation fre-
quency, mean nocturnal Sp O 2 and diabetes mellitus as 
 independent variables and with AHI as the dependent 
variable, only BMI and pack years were found to be sig-
nificantly associated with AHI. The ESS was not signifi-
cantly associated with AHI ( table 4 ). Due to the interre-
lationship between mean nocturnal Sp O 2 and time spent 
at Sp O 2 <90% (r  = –0.78, p  < 0.001), the latter was re-
moved from the final model.
 Discussion 
 This study evaluated the prevalence, possible predic-
tors and associated comorbidities of the overlap syn-
drome in a typical but heterogeneous group of COPD 
 Table 2.  Characteristics according to evidence for OSA
Characteristics AHI ≤10 
(n = 144)
AHI >10 
(n = 33)
p value
Age, years 63.2 (8.6) 65.6 (9.6) 0.152
Male, n 83 (58) 29 (88) 0.001
BMI, kg/m2 24.2 (21.1/28.4) 30.0 (26.9/36.3) <0.001
Systolic blood pressure, mm Hg 126 (115/140) 129 (119/141) 0.597
Current smoker, n 54 (38) 7 (21) 0.076
Pack years 40 (24/53) 40 (28/60) 0.326
ESS score 6 (4/9) 7 (4/11) 0.148
CAT score 16.5 (10.0/21.0) 14.0 (9.0/21.0) 0.418
FEV1 %pred 50.4 (31.0/74.3) 71.2 (55.5/77.5) 0.007
SpO2 daytime, % 95 (93/96) 95 (93/96) 0.565
GOLD stage 2.6 (1.0) 2.2 (0.9) 0.012
Exacerbations per year, n 0 (0/1) 0 (0/0) 0.004
ODI, events/h 3 (1/6) 21 (13/35) <0.001
AHI, events/h 2 (1/5) 20 (15/37) <0.001
Mean nocturnal SpO2, % 92.5 (90.0/94.0) 91.0 (89.0/93.0) 0.070
Time spent at SpO2 <90%, min 38 (8/184) 147 (22/291) 0.016
Arterial hypertension, n 54 (38) 20 (61) 0.015
Cardiovascular disease, n 18 (13) 6 (18) 0.390
Diabetes mellitus, n 14 (10) 11 (33) <0.001
LAMA, n 8 (5) 3 (9) 0.448
LABA + GC, n 19 (13) 4 (12) 0.869
LAMA + LABA + GC, n 68 (47) 9 (27) 0.037
 Age and GOLD stage are presented as the mean with SD in parentheses; other values are n with percentage 
in parentheses, or median with percentiles in parentheses. ODI = Oxygen desaturation index; LAMA = long-
acting muscarinic-antagonist; LABA = long-acting beta-agonist; GC = glucocorticosteroid.
0
10
20
30
40
50
60
70
%
Arterial
hypertension
Diabetes
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Cardiovascular
disease
*
*
$+,
AHI >10
 Fig. 3. Comorbidities in COPD with and without evidence for 
OSA. AHI thresholds represent events per hour.  *  p < 0.05. 
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 patients. We found a prevalence of OSA of almost 20% 
using a threshold of AHI >10 events per hour. BMI and 
pack years were the only significant predictors for OSA in 
the current study. Arterial hypertension and diabetes 
mellitus were more frequent in patients with the overlap 
syndrome.
 The prevalence of the overlap syndrome in our co-
hort was almost 20%. In the middle-aged general popu-
lation the prevalence of OSA with only mild symptoms 
may be up to 30%  [8, 9] . The prevalence of OSA in 
COPD, the overlap syndrome, has not yet been defined 
and varies dependent on the studied population. In 
OSA patients, a high prevalence of COPD ranging from 
11  [10, 11] up to 41%  [12] has been reported. In COPD 
on the other hand, while some studies found a higher 
prevalence of OSA in patients with COPD compared to 
subjects without COPD  [13] , other studies, such as 
Sanders et al.  [11] , found a prevalence of OSA similar to 
the one described in the general population. Sanders et 
al.  [11] analyzed data of a prospective multicenter co-
hort study in which 5,954 patients with and without ob-
structive airway disease were examined. A prevalence of 
OSA (respiratory disturbance index >10 events per 
hour) of 22.3% was found in patients with obstructive 
airway disease. The reported prevalence of OSA in pa-
tients with obstructive airway disease in the latter study 
is comparable to the prevalence of 19% (AHI >10) that 
we found.
 In the multiple regression analysis, BMI and pack 
years were the only predictors for OSA. Our findings are 
in line with previous studies which found a positive as-
sociation between AHI and BMI  [20, 21] . As patients in 
higher COPD GOLD stages also had a lower BMI, pos-
sibly reflecting the systemic effects of this chronic disease, 
we assume that lower BMI was the cause of the lower AHI 
in patients with more severe COPD, since GOLD stages, 
FEV 1 and daytime Sp O 2 were not independent predictors 
for AHI in the multivariate analysis. Generally, a weight 
reduction has been shown to lead to a reduction in AHI 
 [22] .
 There are previous studies investigating the influ-
ence of smoking on OSA. In an observational study 
comparing 108 patients with and 106 patients without 
OSA, Kashyap et al.  [23] found a significantly higher 
prevalence of active smokers in OSA patients compared 
to patients without OSA (35 vs. 18%). Furthermore, 
current smokers had a 2.8-fold higher risk of OSA com-
pared to nonsmokers. In contrast, a cross-sectional 
study with 3,509 sleep-disorder patients by Hoffstein 
 [24] investigating the relationship between smoking 
and OSA did not show an independent association be-
tween the two. Furthermore, there was no independent 
association found between pack years and AHI in the 
latter study. However, these findings are difficult to 
compare with our findings since there are no studies 
investigating the influence of pack years on AHI in 
COPD patients. Therefore, further studies are needed to 
examine the influence of active smoking on OSA in 
COPD.
 Table 3.  Univariate regression analysis of factors possibly associ-
ated with AHI
Characteristics B 95% CI p value
Age 0.05 –0.19/0.28 0.701
Male 5.90 1.73/10.06 0.006
BMI 1.18 0.88/1.48 <0.001
Systolic blood pressure 0.07 –0.04/0.17 0.215
Current smoker –3.41 –7.70/0.88 0.119
Pack years 0.11 0.03/0.18 0.005
ESS score 0.42 –0.06/0.91 0.088
CAT score –0.07 –0.35/0.20 0.598
FEV1 %pred 0.05 –0.04/0.13 0.265
SpO2 daytime –0.83 –1.51/–0.15 0.017
GOLD stage –1.00 –3.05/1.04 0.335
Exacerbations per year –1.42 –2.80/–0.05 0.042
Mean nocturnal SpO2 –0.96 –1.57/–0.36 0.002
Time spent at SpO2 <90% 0.01 –0.00/0.02 0.057
Cardiovascular disease 2.77 –3.22/8.75 0.362
Diabetes mellitus 11.11 5.45/16.77 <0.001
LAMA 4.63 –3.85/13.11 0.283
LABA + GC –0.43 –6.53/5.68 0.891
LAMA + LABA + GC –1.88 –6.01/2.25 0.371
 LAMA  = Long-acting muscarinic-antagonist; LABA  = long-
acting β-agonist; GC = glucocorticosteroid.
 Table 4.  Multiple regression analysis with AHI as the dependent 
variable
Characteristics B 95% CI p value
Male/female 1.57 –2.30/5.44 0.423
BMI 0.93 0.59/1.27 <0.001
Pack years 0.08 0.01/0.15 0.022
ESS score 0.05 –0.39/0.49 0.815
SpO2 daytime –0.70 –1.45/0.05 0.067
Exacerbations per year –0.86 –2.05/0.33 0.154
Mean nocturnal SpO2 –0.10 –0.80/0.60 0.775
Cardiovascular disease –3.22 –8.51/2.08 0.232
Diabetes mellitus 4.57 –0.89/10.04 0.100
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 In daily practice, daytime sleepiness is commonly as-
sessed by the ESS  [17] . We evaluated ESS but did not 
choose to add pathologic ESS in the diagnostic criteria for 
OSA. Abnormal daytime sleepiness assessed by the ESS 
was found in 20% of our study population, but only 8% 
of the participants had both an elevated ESS and AHI, 
thus indicating poor correlation between the two mea-
sures and implying that the ESS cannot be used to iden-
tify COPD patients with possible OSA.
 The pathophysiological background and cause of the 
overlap syndrome is not known. In our study, a preva-
lence of almost 20% of the overlap syndrome was found, 
prompting the assumption that COPD and OSA may be 
linked by common mechanisms. In patients with overlap 
syndrome, the mortality due to cardiovascular events has 
been shown to be higher in comparison to one single dis-
ease alone  [25] . Some preliminary evidence that both dis-
eases may lead to systemic inflammation  [26] , and accel-
erate atherosclerosis  [27, 28] and vascular dysfunction 
 [29, 30] , and thus might increase comorbidities such as 
arterial hypertension  [31] , have been presented before. 
This is in line with our findings that those with the over-
lap syndrome had a higher rate of arterial hypertension 
and diabetes.
 The present study has some limitations. As it was an 
observational study we have to rely on the information 
given by the patients concerning ESS and CAT, exacerba-
tion rate, smoking history, medication use and comor-
bidities. As a cross-sectional study evaluates one time 
point only, no conclusion can be made in our study re-
garding the causal relationship between COPD and OSA. 
When interpreting a sleep study, the chosen device for 
examination is of importance. In previous studies the 
 ApneaLink has been shown to underestimate the AHI 
score in subjects with severe OSA, and slightly overesti-
mate AHI in patients with very mild OSA  [32] . However, 
the addition of oximetry data (oxygen desaturation index) 
showed an improvement of the specificity, reducing false 
positive results  [19] . Further unattended polysomnogra-
phy in an outpatient setting has been applied in previous 
studies  [13, 11] and it has been shown to be cost-effective 
and convenient for the patient, providing validated and 
highly sensitive and specific results not inferior to those 
collected by laboratory polysomnography  [33–35] .
 In this study, only excessive sleepiness (ESS) was con-
sidered as a possible clinical predictor for OSA in addi-
tion to anthropometric data and comorbidities. Further 
studies will need to investigate the usefulness of other 
possible clinical predictors for OSA in patients with 
COPD, such as a history of snoring or witnessed apneas.
 In conclusion, the present observational study in a 
Swiss cohort of COPD patients showed a prevalence of 
OSA of almost 20%. BMI and pack years were the only 
clinical predictors for OSA in our cohort, while ESS can-
not be used to identify COPD patients with OSA. Comor-
bidities such as arterial hypertension and diabetes were 
found more often in patients with the overlap syndrome 
compared to patients with COPD alone, possibly provid-
ing an explanation for the high mortality found in these 
patients. 
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